Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bazedoxifene Acetate

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Bazedoxifene Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Postmenopausal osteoporosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective estrogen receptor modulators
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bazedoxifene Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bazedoxifene Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The PROMISE Study: Duavee in Women With DCIS

    NCT02694809 · start 2017-01

    Registered record
    Registry ID
    NCT02694809
    Conditions
    Ductal Breast Carcinoma In Situ; Postmenopausal
    Interventions
    Conjugated Estrogens/Bazedoxifene; Laboratory Biomarker Analysis; Pharmacological Study; Placebo; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-01
    Completion
    2024-06-19
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuctal Breast Carcinoma In Situ; Postmenopausal
    InterventionConjugated Estrogens/Bazedoxifene; Laboratory Biomarker Analysis; Pharmacological Study; Placebo +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Phase 1 Drug Drug Interaction Clinical Trial of C1-R215 and C2-R215 in Healthy Male Volunteers

    NCT03005340 · start 2016-12

    Registered record
    Registry ID
    NCT03005340
    Conditions
    Healthy
    Interventions
    Treatment B; Treatment C; Treatment BC
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2016-12
    Completion
    2017-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTreatment B; Treatment C; Treatment BC
    PhasePhase 1
    Registry statusUnknown

  • Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation

    NCT02729701 · start 2016-05

    Registered record
    Registry ID
    NCT02729701
    Conditions
    Breast Cancer
    Interventions
    Duavee
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-05
    Completion
    2019-06
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDuavee
    PhasePhase 2
    Registry statusCompleted

  • A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

    NCT02710214 · start 2016-02

    Registered record
    Registry ID
    NCT02710214
    Conditions
    Menopause; Multiple Sclerosis
    Interventions
    Tissue Selective Estrogen Complex; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-02
    Completion
    2019-04-24
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Multiple Sclerosis
    InterventionTissue Selective Estrogen Complex; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

    NCT02602704 · start 2015-12-29

    Registered record
    Registry ID
    NCT02602704
    Conditions
    Arthritis, Rheumatoid
    Interventions
    Bazedoxifene; Calcium/Vit D
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-12-29
    Completion
    2018-12-01
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthritis, Rheumatoid
    InterventionBazedoxifene; Calcium/Vit D
    PhasePhase 4
    Registry statusCompleted

  • Raising Insulin Sensitivity in Post Menopause

    NCT02274571 · start 2015-09

    Registered record
    Registry ID
    NCT02274571
    Conditions
    Menopause
    Interventions
    TSEC (Tissue-selective estrogen complexes); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2015-09
    Completion
    2017-04-11
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause
    InterventionTSEC (Tissue-selective estrogen complexes); Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

    NCT02448771 · start 2015-07-09

    Registered record
    Registry ID
    NCT02448771
    Conditions
    Breast Cancer Stage IV; Unresectable Locally Advanced Invasive Breast Cancer; Metastatic Invasive Breast Cancer
    Interventions
    Palbociclib; Bazedoxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-07-09
    Completion
    2021-03-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Stage IV; Unresectable Locally Advanced Invasive Breast Cancer; Metastatic Invasive Breast Cancer
    InterventionPalbociclib; Bazedoxifene
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)

    NCT02237079 · start 2014-12

    Registered record
    Registry ID
    NCT02237079
    Conditions
    Obesity; Glucose Homeostasis; Postmenopausal Symptoms
    Interventions
    Bazedoxifene/Conjugated Estrogens (BZA/CE); Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-04
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Glucose Homeostasis; Postmenopausal Symptoms
    InterventionBazedoxifene/Conjugated Estrogens (BZA/CE); Placebo Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women

    NCT02100553 · start 2014-04

    Registered record
    Registry ID
    NCT02100553
    Conditions
    Healthy
    Interventions
    CE/BZA; Itraconazole; CE/BZA; CE/BZA; Itraconazole; CE/BZA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2014-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCE/BZA; Itraconazole; CE/BZA; CE/BZA +2 more
    PhasePhase 1
    Registry statusCompleted

  • Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice

    NCT01793142 · start 2013-10-24

    Registered record
    Registry ID
    NCT01793142
    Conditions
    Osteoporosis
    Interventions
    Viviant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-10-24
    Completion
    2017-05-31
    Enrolment
    3,430

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionViviant
    PhaseNot recorded
    Registry statusCompleted

  • Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women

    NCT02090400 · start 2013-05

    Registered record
    Registry ID
    NCT02090400
    Conditions
    Osteoporosis, Postmenopausal
    Interventions
    Bazedoxifene; Calcium/Vit D
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-05
    Completion
    2015-07
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Postmenopausal
    InterventionBazedoxifene; Calcium/Vit D
    PhasePhase 4
    Registry statusCompleted

  • A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

    NCT01634789 · start 2012-08

    Registered record
    Registry ID
    NCT01634789
    Conditions
    Healthy
    Interventions
    bazedoxifene; bazedoxifene; bazedoxifene; bazedoxifene/conjugated estrogens
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-08
    Completion
    2012-11
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionbazedoxifene; bazedoxifene; bazedoxifene; bazedoxifene/conjugated estrogens
    PhasePhase 1
    Registry statusTerminated

  • Comparison Between Raloxifene and Bazedoxifene

    NCT01973738 · start 2012-01

    Registered record
    Registry ID
    NCT01973738
    Conditions
    Selective Estrogen Receptor Modulator
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2012-01
    Completion
    2018-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSelective Estrogen Receptor Modulator
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)

    NCT01470326 · start 2011-11

    Registered record
    Registry ID
    NCT01470326
    Conditions
    Osteoporosis
    Interventions
    Bazedoxifene
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-11
    Completion
    2016-06
    Enrolment
    3,187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionBazedoxifene
    PhaseNot recorded
    Registry statusCompleted

  • Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

    NCT01416194 · start 2011-07-25

    Registered record
    Registry ID
    NCT01416194
    Conditions
    Osteoporosis, Postmenopausal
    Interventions
    Bazedoxifene; Bisphosphonate; Raloxifene
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-07-25
    Completion
    2019-04-30
    Enrolment
    10,497

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Postmenopausal
    InterventionBazedoxifene; Bisphosphonate; Raloxifene
    PhaseNot recorded
    Registry statusCompleted